Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (Nasdaq: TLSA) announced the closure of a registered direct offering, issuing 11,009,615 American Depositary Shares (ADSs) at $5.20 per share, raising approximately $57.25 million. The proceeds will support clinical development of Foralumab, clinical trials for HCC patients with Milciclib, and expedite development of TZLS-501 for COVID-19. The total number of Ordinary Shares post-offering is now 190,559,823. ThinkEquity acted as the placement agent for the offering.

Tiziana Life Sciences plc (NASDAQ: TLSA) has signed agreements with four contract research organizations (CROs) to expedite the clinical development of TZLS-501, a fully human monoclonal antibody targeting IL-6R for COVID-19 treatment. The company plans to initiate human clinical trials in Q1 2021. Key partners include FHI Clinical, STC Biologics, Sciarra Labs, and ITR Laboratories Canada, which will assist with GMP manufacturing, safety studies, and inhalation technology. TZLS-501 aims to address cytokine release syndrome by depleting IL-6 levels directly in patients' lungs.

Tiziana Life Sciences (NASDAQ: TLSA) has reported issuing 2,043,000 ordinary shares in July 2020 under its ATM sales agreement, raising $4,371,289. The total number of ordinary shares now stands at 168,540,593, with each share providing one vote in company meetings. Tiziana is advancing its clinical programs, including phase 2 studies for Foralumab, a pioneering anti-CD3 monoclonal antibody aimed at treating autoimmune conditions like Crohn's Disease and multiple sclerosis, alongside developing treatments for COVID-19.

Tiziana Life Sciences (NASDAQ: TLSA) announced the submission of a patent application for the nasal administration of Foralumab, an anti-CD3 monoclonal antibody, as a treatment for COVID-19. This innovative method could enhance immune response and reduce cytokine storms in patients. The company also reported successful Phase 1 trials for both nasal and oral administrations of Foralumab, which showed positive immunomodulatory effects and no severe toxicities. Tiziana holds exclusive rights for this delivery method, aligning with its focus on advancing immunotherapeutic approaches to treat various diseases.

Tiziana Life Sciences plc announced its intention to apply for a standard listing of its ordinary shares on the Official List and admission to trading on the London Stock Exchange's main market. The directors believe this move will enhance the company's global profile, increase trading liquidity, and attract a broader base of investors. Importantly, the company will not issue new shares or raise capital through this listing. A formal notice regarding the cancellation of trading on the AIM market will follow, with expectations to publish a prospectus by late Q3 or early Q4 2020.

Tiziana Life Sciences (Nasdaq: TLSA) announced an investor webinar on July 30, 2020, at 4:00 p.m. U.S. Eastern, where CEO Kunwar Shailubhai will discuss the company’s development pipeline and milestones. The webinar includes a live Q&A session. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases. Key products include TZLS-501, a monoclonal antibody for COVID-19 treatment, and Foralumab, a fully human anti-CD3 mAb aimed at autoimmune diseases.

Tiziana Life Sciences (TLSA), a biotechnology firm, has issued 88,580 new ordinary shares at 93 pence each through the exercise of warrants, generating £82,379 in cash. These shares will be admitted to trading on AIM around July 30, 2020, bringing the total number of ordinary shares to 166,497,593. The new shares rank pari passu with existing shares. Tiziana focuses on developing therapies for oncology, inflammation, and infectious diseases, including its work on Foralumab, an anti-CD3 monoclonal antibody.

Tiziana Life Sciences (Nasdaq: TLSA) announced the appointment of John Brancaccio as a Non-executive Director. With extensive experience in finance within the pharmaceutical and biotechnology sectors, Brancaccio has held significant roles, including CFO positions at various companies. He currently serves on the boards of multiple firms, including Cardiff Oncology, Inc. This appointment comes as Tiziana prepares to advance its clinical programs, including phase 2 studies for its novel treatment for autoimmune diseases, indicating the company's focus on enhancing its leadership team to support future growth.

Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) announced that all resolutions were passed at its Annual General Meeting held on July 16, 2020. The meeting took place at 10:00 a.m. in London and New York. The results of the proxy voting will be made available on the Company’s website. Tiziana focuses on discovering and developing novel therapeutic molecules for oncology and immunology, including milciclib and foralumab, a fully human anti-CD3 monoclonal antibody currently in clinical development for various autoimmune and inflammatory diseases.